



**APONTIS PHARMA AG
Monheim on the Rhine**

– WKN A3CMGM –

– ISIN DE000A3CMGM5 –

Unique identifier of the event: APPH052023HV

**Invitation to the Annual General Meeting
(virtual Annual General Meeting)**

Dear Shareholders,

we invite you to the

Annual General Meeting of APONTIS PHARMA AG,

which will take place on Friday, **12 May 2023**, at **10:00** a.m. CEST,

as a virtual Annual General Meeting pursuant to Section 26n para. 1 of the Introductory Act to the German Stock Corporation Act ("EGAktG"), with the consent of the Supervisory Board, without the physical presence of the shareholders or their proxies (with the exception of the proxies appointed by the Company).

The entire Annual General Meeting will be webcast live in video and audio format for properly registered shareholders of APONTIS PHARMA AG and their proxies via the Internet at

<https://apontis-pharma.de/en/annual-general-meeting>

in the password-protected Internet service for the Annual General Meeting of APONTIS PHARMA AG ("password-protected Internet service"). Shareholders' voting rights may be exercised - by the shareholders themselves or by proxies - exclusively by means of electronic postal voting or by granting power of attorney to the proxies appointed by the Company.

The venue of the Annual General Meeting within the meaning of the German Stock Corporation Act is Stadttor 1, 40219 Düsseldorf, Germany. Physical attendance by shareholders or their proxies (with the exception of the proxies appointed by the Company) is excluded.

For details on the rights of shareholders and their proxies, please refer to the section "II Further information and notes on the Annual General Meeting", which is printed after the agenda.

I. Agenda

1. **Presentation of the approved annual financial statements of APONTIS PHARMA AG as of 31 December 2022, and the approved consolidated financial statements as of 31 December 2022, and the group management report for the financial year 2022, as well as the report of the Supervisory Board for the financial year 2022**

The documents presented for agenda item 1 can be viewed on the website at

<https://apontis-pharma.de/en/annual-general-meeting>

from the time the Annual General Meeting is convened. They will also be accessible during the Annual General Meeting.

The Supervisory Board has already approved the annual financial statements and consolidated financial statements of APONTIS PHARMA AG prepared by the Executive Board; the annual financial statements have thus been adopted. In accordance with the statutory provisions, no resolution is therefore planned for agenda item 1.

2. **Resolution on the discharge of the members of the Executive Board for the financial year 2022**

The Executive Board and Supervisory Board propose

that the actions of the members of the Executive Board holding office in fiscal year 2022 be approved for that period.

3. **Resolution on the discharge of the members of the Supervisory Board for the financial year 2022**

The Executive Board and Supervisory Board propose

that the actions of the members of the Supervisory Board holding office in the fiscal year 2022 be approved for that period.

4. **Election of the auditor and the group auditor for the financial year 2023**

On the recommendation of its Audit Committee, the Supervisory Board proposes that the following resolution be adopted:

Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Bonn, is appointed as auditor of the annual financial statements and as group auditor for the fiscal year 2023.

5. **Resolution on amendments to the Articles of Association in connection with virtual general meetings**

With the "Act on the Introduction of Virtual General Meetings of Stock Corporations and Amendments to Cooperative, Insolvency, and Restructuring Law Provisions" of 20 July 2022 (Federal Law Gazette of 26 July 2022, page 1166 et seq.), the legislator has permanently anchored the virtual Annual General Meeting in the German Stock Corporation Act (*Aktengesetz* - "AktG"). However, the convening of virtual Annual General Meetings after 31 August 2023 is only possible on the basis of a corresponding authorisation in the Articles of Association. According to the newly introduced Section 118a para. 1 sentence 1 AktG, the Articles of Association may therefore provide or authorise the Executive Board to provide that the Annual General Meeting is held without the physical presence of the shareholders or their proxies at the location of the Annual General Meeting. A corresponding provision in the Articles

of Association must be limited in time, with a maximum period of five years from registration of the corresponding amendment to the Articles of Association in the commercial register of the Company.

The Executive Board and the Supervisory Board are of the opinion that the virtual Annual General Meeting format as such has proven its worth in the past two years and that the option of holding Annual General Meetings virtually should be retained in the future. The virtual Annual General Meeting in the format provided for by the corresponding new provisions in the Stock Corporation Act adequately safeguards the rights of shareholders and, in particular, provides for direct interaction between shareholders and management during the meeting via video communication and electronic communication channels in a manner similar to the conventional Annual General Meeting in person.

However, there may be Annual General Meetings with items on the agenda for which interaction in the presence of the shareholders and their proxies appears more appropriate than virtual interaction. It therefore seems sensible not to stipulate directly in the Articles of Association that a virtual Annual General Meeting should be held, but to authorise the Executive Board to decide in advance of each Annual General Meeting whether the meeting should be held as a virtual meeting or as a meeting in which shareholders are present.

Such authorisation of the Executive Board is to be resolved, whereby use is not to be made of the maximum possible term of five years provided for by law. Instead, only an authorisation to hold virtual Annual General Meetings within a period of two years after registration of the amendment to the Articles of Association is to be resolved. For future Annual General Meetings, a decision is to be made separately in each case, taking into account the circumstances of the individual case, as to whether to make use of the authorisation and hold an Annual General Meeting as a virtual Annual General Meeting. The Executive Board will make its decisions taking into account the interests of the Company and its shareholders and in particular the protection of shareholders' rights as well as aspects of health protection of the participants, effort and costs, and sustainability considerations.

In doing so, the Executive Board will also take into account that there may be Annual General Meetings with agenda items at which the personal presence of shareholders and their proxies may be more suitable than a virtual format. If the Executive Board decides to hold a virtual Annual General Meeting and also makes use of the option of shifting part of the right to ask questions to the run-up to the meeting, it will ensure, within the framework of the statutory requirements, that the right to ask questions is not unreasonably restricted either in the run-up to the meeting or at the Annual General Meeting.

In the case of the virtual Annual General Meeting, the members of the Supervisory Board shall be permitted to participate in the Annual General Meeting by means of video and audio transmission. If direct interaction of all or individual members of the Supervisory Board with the Annual General Meeting is required, this will be made possible by directly connecting these Supervisory Board members by means of the planned two-way communication.

The Executive Board and Supervisory Board propose that the following resolutions be adopted:

5.1 Resolution on the amendment of § 16 of the Articles of Association to authorise the Executive Board to hold virtual general meetings

The following new paragraph 6 shall be inserted in § 16 of the Articles of Association:

16.6 The Executive Board is authorised to provide for the meeting to be held without the physical presence of the shareholders or their proxies at the location of the Annual General Meeting (virtual Annual General Meeting). The authorisation shall apply to the holding of virtual General Meetings within a period of two years after entry of this provision of the Articles of Association in the commercial register of the Company. All provisions of these Articles of Association relating to shareholders' meetings shall apply to the virtual shareholders' meeting unless otherwise provided by mandatory law or expressly stated in these Articles of Association.

5.2 Resolution on the amendment of § 16 of the Articles of Association to enable the participation of Supervisory Board members by means of video and audio transmission

The following new paragraph 7 shall be inserted in § 16 of the Articles of Association:

16.7 In the event of a virtual Annual General Meeting, members of the Supervisory Board shall be permitted to participate in the Annual General Meeting by means of video and audio transmission.

II. Further information and notes to the Annual General Meeting

1. Virtual Annual General Meeting / Transmission with video and audio / Webcasting

With the approval of the Supervisory Board, the Executive Board has resolved to hold the Annual General Meeting in accordance with Section 118a AktG in conjunction with Section 26n para. 1 EAktG as a virtual Annual General Meeting without the physical presence of shareholders or their proxies. A physical presence of the shareholders and their proxies at the location of the Annual General Meeting is excluded.

For shareholders or their proxies who have properly registered for the Annual General Meeting, the entire Annual General Meeting, including any answers to questions and the votes, will be webcast live with video and audio on the APONTIS PHARMA AG website at

<https://apontis-pharma.de/en/annual-general-meeting>

in the password-protected Internet service. Via the password-protected Internet service, properly registered shareholders (and, if applicable, their proxies) can, among other things, exercise the shareholder rights granted to them in accordance with the procedures provided for this purpose. The personal access data required for this (access code and access password) will be sent to shareholders or their proxies with the "AGM ticket" after registration for the Annual General Meeting.

The use of the password-protected Internet service by a proxy requires that the proxy receives the corresponding access data. Authorised intermediaries, shareholders' associations, proxy advisors, and other persons treated as such under Section 135 para. 8 AktG may also use the password-protected Internet service. The Company will provide them with electronic access on request.

When entering the virtual Annual General Meeting using the password-protected Internet service during the virtual Annual General Meeting on 12 May 2023, the shareholders or their proxies will be electronically connected to the virtual Annual General Meeting.

2. Attendance at the virtual Annual General Meeting

Pursuant to Section 16.3 of the Articles of Association, shareholders who have registered for the Annual General Meeting in text form and provided the Company with evidence of their shareholding are entitled to attend the virtual Annual General Meeting and exercise their voting rights. Proof of share ownership must be provided in the form of a special certificate issued in text form by the custodian bank in German or English. Pursuant to Section 16.4 of the Articles of Association in conjunction with Section 123 para. 4 AktG, the proof of shareholding must refer to the beginning of the 21st day before the Annual General Meeting, i.e. at the beginning of 21 April 2023, 00:00 hours CEST (record date).

The registration and proof of shareholding must be received by the Company at the latest six days before the Annual General Meeting, i.e. no later than 5 May 2023, 24:00 hours CEST, at the following address or e-mail address:

APONTIS PHARMA AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Email: anmeldung@better-orange.de

After receipt of the registration and the proof of their shareholding at the above address, the shareholders or their proxies will be sent an AGM ticket, which contains an integrated proxy form and a proxy and instruction form for the AGM. The relevant forms are also available on the Internet on the APONTIS PHARMA AG website at

<https://apontis-pharma.de/en/annual-general-meeting>.

In order to ensure that the AGM ticket is received in good time, we would ask shareholders to ensure that their registration and proof of share ownership are received by the Company in good time. Receipt of the AGM ticket is not a prerequisite for issuing proxies and instructions (to the Company's proxies) by form, but all options of the password-protected Internet service can only be used with the aid of the access data printed on the AGM ticket.

The shares are not blocked by registration for the Annual General Meeting. Shareholders can therefore continue to freely dispose of their shares even after registration. In relation to the Company, only those shareholders who have provided proof of share ownership as of the record date are deemed to be shareholders for the purpose of participating in the virtual Annual General Meeting and exercising voting rights; changes in the shareholding after the record date are irrelevant for the scope and exercise of participation and voting rights.

3. Voting by electronic vote (postal vote)

Shareholders and their proxies may submit their votes by way of electronic communication (postal vote). Only those shareholders - in person or by proxy - who have properly registered and provided evidence of their shareholding are entitled to exercise their voting rights by way of electronic postal voting.

Voting takes place electronically (with the corresponding access data, see above under 1.) via the password-protected Internet service in accordance with the procedure provided for this purpose on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting>.

Postal votes can be submitted, changed, or revoked via the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> in accordance with the procedure provided for this purpose from 21 April 2023 until the time the voting is closed by the chairman of the meeting at the virtual Annual General Meeting on 12 May 2023.

4. Procedure for voting by proxy

Shareholders and their proxies may also have their voting rights exercised by a proxy, for example by the depositary bank, a shareholders' association, or another person of their choice.

However, proxies (with the exception of the Company's proxies) cannot physically participate in the virtual shareholders' meeting either. They can only exercise voting rights for shareholders they represent by means of electronic postal voting or by issuing (sub)powers of attorney to the proxies nominated by the Company.

The use of the password-protected Internet service by the authorised representative requires that the authorised representative receives the corresponding access data.

As a service, the Company offers its shareholders and their proxies the opportunity to be represented at the Annual General Meeting by proxies appointed by the Company in accordance with instructions issued. The proxies will exercise the voting rights of the shareholders in accordance with the instructions given to them. Even if a proxy has been granted, they are only authorised to exercise voting rights if an express instruction has been issued. The proxies will not accept any instructions to ask questions or propose motions or to object to resolutions of the Annual General Meeting.

Proper registration by the shareholder or the proxy is also required in all cases of authorisation; furthermore, proof of the shareholder's shareholding is also required in these cases.

The granting of the proxy, its amendment, revocation, and proof of authorisation towards the Company must be in text form. Exceptions may be made for the granting of powers of attorney to intermediaries (e.g. banks) and - insofar as they are treated in the same way as such intermediaries pursuant to Section 135 para. 8 AktG – to shareholders' associations, proxy advisors, and persons who offer themselves to shareholders on a business basis for the exercise of voting rights at the Annual General Meeting, and for the revocation of such powers of attorney and the corresponding evidence towards the Company; with regard to the form to be observed in this respect, we request our shareholders to consult with the aforementioned persons.

The issuance of instructions to the proxies of the Company as well as the revocation or amendment of these instructions require text form.

The following address or email address will be available until 24:00 hours CEST on 11 May 2023 for the granting of proxies to the Company, for the transmission of proof of a proxy declared to the proxies, and for the amendment and revocation of proxies:

APONTIS PHARMA AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany

Email: apontis-pharma@better-orange.de

In addition, the password-protected Internet service (with the corresponding access data, see above under 1.) will be available for this purpose - from 21 April 2023 and also during the virtual Annual General Meeting - in accordance with the procedure provided for this purpose on the website of APONTIS PHARMA AG under <https://apontis-pharma.de/en/annual-general-meeting>.

The granting, revocation, and amendment of instructions to the proxies of the Company are possible at the aforementioned address or e-mail address until 11 May 2023, 24:00 hours CEST.

In addition, the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> will be available for this purpose with the corresponding access data (see 1. above) from 21 April 2023 until the time of the closing of the voting by the chairman of the meeting in the virtual general meeting on 12 May 2023 in accordance with the procedure provided for this purpose.

5. Submission of statements

Properly registered shareholders or their proxies have the right, pursuant to Section 130a para. 1 to para. 4 AktG, to submit statements on the items on the agenda in text form or in video format by way of electronic communication. For this purpose, the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> is available to them with the corresponding access data (see above under 1.). Statements in text form are to be submitted in accordance with the procedure provided for this purpose as a file in PDF format with a recommended maximum file size of 50 MB. Statements in video format are to be submitted in accordance with the designated procedure in the file formats MPEG-4 or MOV; they may not exceed a file size of 1 GB. Multiple submissions are possible. Only those statements in video format in which the shareholder or his proxy himself appears are admissible. By submitting a statement, the shareholder or his proxy agrees that the statement will be made available on the password-protected Internet service under his name.

Statements must be submitted no later than five days before the meeting, i.e. no later than 24:00 hours CEST on 6 May 2023. Unless it is exceptionally permitted to refrain from making them available pursuant to Section 130a para. 3 sentence 4 AktG, submitted statements on the agenda items will be made available no later than four days prior to the Annual General Meeting, i.e. no later than on 7 May 2023, 24:00 hours CEST, in the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting>, which is only accessible to properly registered shareholders or their proxies with the corresponding access data (see 1. above).

Motions and nominations, questions and objections against resolutions of the Annual General Meeting in the context of statements submitted in text form or in video format will not be considered at the Annual General Meeting; the filing of motions or the submission of nominations (see 8.), the exercise of the right to information (see 9.) as well as the filing of objections against resolutions of the Annual General Meeting (see 7.) is only possible via the channels described separately in this invitation.

6. Right to speak

Shareholders or their proxies who are electronically connected to the Annual General Meeting have the right to speak at the meeting by way of video communication. From the beginning of the Annual General Meeting, a virtual registration table for registering to speak will be maintained via the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> (for the corresponding access data, see 1. above), via which the shareholders or their proxies can register their speech. The right to speak also includes, in particular, the right to submit motions and nominations pursuant to Section 118a para. 1 Sentence 2 No. 3 AktG (see also Section 8. below), as well as the right to request information pursuant to Section 131 para. 1 AktG (see also Section 9. below).

In accordance with Section 17.2 of the Company's Articles of Association, the chairman of the meeting may determine the order of speeches and impose reasonable time limits on shareholders' rights to ask questions and speak. In particular, he is entitled, at the beginning of the Annual General Meeting or during its course, to set an appropriate time limit for the entire course of the Annual General Meeting, for individual agenda items, or for individual questions or speeches.

The entire virtual Annual General Meeting, including video communication, is handled via the BetterMeeting system from Better Orange IR & HV AG using a password-protected Internet service. Shareholders or their proxies who wish to register their speech via the virtual registration table require either a non-mobile device (PC, notebook, laptop) with Chrome browser version 89 or higher, Edge browser version 88 or higher, or Safari browser version 13.1 or higher, or a mobile device (e.g. smartphone or tablet). Mobile end devices with ANDROID operating system require Chrome from version 89 as the installed browser; mobile end devices with iOS operating system require Safari from version 13.1 as the installed browser. A camera and microphone that can be accessed from the browser must be available on the end devices for speech contributions. No further installation of software components or apps on the end devices is required. Persons who have registered for a speech via the virtual registration table will be activated for their speech in the password-protected Internet service. The Company reserves the right to check the functionality of the video communication between the shareholder or proxy and the Company during the meeting and before the speech and to reject the speech if the functionality is not ensured.

7. Submission of objections

Shareholders or their proxies who are electronically connected to the Annual General Meeting have the right to object to a resolution of the Annual General Meeting via the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> in accordance with the procedure provided for this purpose with the corresponding access data (see above under 1.) during the Annual General Meeting, i.e. from the opening of the Annual General Meeting until its closing, for the record of the notary public.

8. Motions and nominations by shareholders or their proxies

Motions by shareholders or their proxies against a proposal by the management on a specific agenda item in accordance with section 126 para. 1 AktG and election proposals by shareholders or their proxies for the election of Supervisory Board members or auditors in accordance with section 127 AktG must be addressed exclusively to:

APONTIS PHARMA AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany

Email: antraege@better-orange.de

Countermotions and nominations by shareholders or their proxies that are received at this address or e-mail address by 27 April 2023, 24:00 hours CEST, and that meet the further requirements of Sections 126, 127 AktG, and any comments by the administration will be made available to the other shareholders on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting>. Motions addressed otherwise will not be considered.

Motions or nominations for election by shareholders or their proxies which are to be made accessible pursuant to Section 126 or Section 127 AktG shall be deemed to have been made at the time they are made accessible. The Company allows voting rights on these motions or nominations to be exercised as soon as the shareholder submitting the motion or nomination has been properly legitimized and properly registered for the Annual General Meeting.

Shareholders or their proxies who are connected to the Annual General Meeting also have the right to submit motions and nominations in the meeting by way of video communication within the scope of their right to speak (see in detail above under 6.).

9. Right to information

Pursuant to Section 131 para. 1 AktG, the Executive Board must provide each shareholder with information on the Company's affairs upon request at the Annual General Meeting, provided that the information is necessary for a proper evaluation of an item on the agenda and there is no right to refuse to provide information. The duty of the Executive Board to provide information also extends to the legal and business relations of the Company with its affiliated companies. Furthermore, the duty to provide information also concerns the situation of the APONTIS PHARMA Group and the companies included in the APONTIS PHARMA consolidated financial statements.

It is intended that the chairman of the Annual General Meeting will stipulate that the aforementioned right to information pursuant to Section 131 para. 1 AktG may be exercised at the Annual General Meeting exclusively by way of video communication, i.e., as part of the exercise of the right to speak (see 6. below).

Section 131 para. 4 sentence 1 AktG stipulates that if a shareholder has been provided with information outside the Annual General Meeting due to his capacity as a shareholder, this information must be provided to any other shareholder or his proxy at his request in the Annual General Meeting, even if it is not necessary for the proper assessment of the item on the agenda.

In addition, section 131 para. 5 sentence 1 AktG stipulates that if a shareholder is refused information, he may request that his question and the reason for which the information was refused be recorded in the minutes of the meeting.

Within the framework of the virtual Annual General Meeting, it is ensured that shareholders or their proxies who are electronically connected to the Annual General Meeting can submit their requests pursuant to Section 131 para. 4 sentence 1 AktG as well as their requests pursuant to Section 131 para. 5 sentence 1 AktG not only by way of video communication, i.e. within the framework of the right to speak and the procedure provided for this purpose (see above 6.), also by way of electronic communication via the password-protected Internet service on the website of APONTIS PHARMA AG at <https://apontis-pharma.de/en/annual-general-meeting> in accordance with the procedure provided for this purpose with the corresponding access data (see 1. above) in the Annual General Meeting.

10. Information on data protection

The Company processes the following categories of personal data of its shareholders and their proxies in the course of holding the Annual General Meeting: contact data (e.g. name or email address), information on the shares held by each individual shareholder (e.g. number of shares) and administrative data (e.g. the AGM ticket number, access ID and password for the password-protected Internet service). The processing of personal data in the context of the Annual General Meeting is based on Section 6 para. 1 lit. c of the General Data Protection Regulation ("GDPR"). According to this, processing of personal data is lawful if the processing is necessary for compliance with a legal obligation. The Company is legally obliged to invite its shareholders to participate in an Annual General Meeting and to enable them to exercise their shareholder rights. In order to comply with this obligation, the processing of the above categories of personal data is indispensable. Without providing their personal data, the Company's shareholders will not be able to register for and participate in the Annual General Meeting.

The Company is responsible for data processing. The contact details of the responsible person are:

APONTIS PHARMA AG
Alfred-Nobel-Str. 10,
40789 Monheim (Germany)
Tel. +49 2173 8955 4949
Fax +49 2173 8955 4941

E-Mail: datenschutz@apontis-pharma.de

As a matter of principle, personal data relating to the shareholders of the Company will not be disclosed to third parties. By way of exception, third parties are given access to this data if they have been commissioned by the Company to provide services in connection with the holding of the Annual General Meeting. These are typical AGM service providers such as AGM agencies, lawyers, or auditors. The service providers only receive personal data to the extent necessary for the provision of the service.

As part of the statutory right to inspect the list of attendees at the Annual General Meeting, other attendees, shareholders and shareholder representatives connected electronically to the meeting may inspect the data recorded in the list of attendees. Personal data is also published in connection with requests for additions to the agenda, counter motions, or nominations for

election which require publication. The same applies to the disclosure of submitted comments pursuant to Section 118a para. 1 sentence 2 no. 6 AktG.

The above data will be kept for up to 3 years (but not less than 2 years) after the end of the Annual General Meeting, depending on the individual case, and will then be deleted, unless further processing of the data is still required in the individual case to process applications, decisions or legal proceedings relating to the Annual General Meeting.

Shareholders have the right to receive information free of charge upon request about the personal data stored about them. In addition, shareholders have the right to have inaccurate data relating to them corrected, the right to request the restriction of processing of data that has been processed too extensively, and the right to have personal data that has been processed unlawfully or stored for too long deleted (insofar as this does not conflict with any legal obligation to retain data and no other reasons pursuant to Section 17 para. 3 GDPR). In addition, shareholders have the right to transfer all data they have provided to the Company in a common file format (right to "data portability"). To exercise their rights, it is sufficient for the respective shareholder to send an email to datenschutz@apontis-pharma.de.

In addition, shareholders also have the right to file a complaint with a data protection supervisory authority.

You can reach the data protection officer of APONTIS PHARMA AG under the following contact details:

APONTIS PHARMA AG
Data Protection Officer
Alfred-Nobel-Str. 10
40789 Monheim
Tel.: +49 2173 8955 2204
Email: peter.hagedorn@apontis-pharma.de

Monheim am Rhein, March 2023

APONTIS PHARMA AG

The Executive Board

Minimum information pursuant to Section 125 (1) German Stock Corporation Act (AktG) in connection with Section 125 (5) AktG, Article 4 (1) and Table 3 Blocks A to C of the Annex to Implementing Regulation (EU) 2018/1212

Type of Information	Description
A. Specification of the message	
1. Unique identifier of the event	APPH052023HV
2. Type of message	Meeting notice of a General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: NEWM]
B. Specification of the issuer	
1. ISIN	DE000A3CMGM5
2. Name of issuer	APONTIS PHARMA AG
C. Specification of the meeting	
1. Date of the General Meeting	12.05.2023 [format pursuant to Implementing Regulation (EU) 2018/1212: 20230512]
2. Time of the General Meeting	10:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 08:00 UTC]
3. Type of the General Meeting	Virtual Annual General Meeting without the physical attendance of shareholders or their proxy representatives [format pursuant to Implementing Regulation (EU) 2018/1212: GMET]
4. Location of the General Meeting	Virtual General Meeting: https://apontis-pharma.de/hauptversammlung In accordance with the German Stock Corporation Act: Stadttor 1, 40219 Düsseldorf, Germany
5. Record Date	21.04.2023, 00:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 30230420; 22:00 UTC]
6. Uniform Resource Locator (URL)	https://apontis-pharma.de/hauptversammlung